This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Brown R, Turk F, Groot M, Dale P.Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands. European Respiratory Journal Supplement 30 (Suppl. 51): 194 (plus poster) abstr. P1187, Sep 2007
Glick H, Briggs A, Lozano-Ortega G, Spencer M, Calverley P, Vestbo J.Is treatment with ICS and LABA good value for money for COPD? Multinational cost-effectiveness analysis of the TORCH study. European Respiratory Journal Supplement 30 (Suppl. 51): 194, Sep 2007
Ott S, Welte T, Ernen C, Kothe H, Bauer T.Cost of treatment failure in community-acquired pneumonia. European Respiratory Journal Supplement 30 (Suppl. 51): 195, Sep 2007
Bolin K, Gilljam H, Mörk A-C, Lindgren B.Costs and benefits accruing from smoking cessation with varenicline. European Respiratory Journal Supplement 30 (Suppl. 51): 503, Sep 2007
Rights and permissions
About this article
Cite this article
News from ERS. Pharmacoecon. Outcomes News 540, 11 (2007). https://doi.org/10.2165/00151234-200705400-00021
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705400-00021